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Development and Potential Role of Type-2 Sodium-Glucose 
Transporter Inhibitors for Management of Type 2 Diabetes
Timothy Colin Hardman · Simon William Dubrey
ABSTRACT
There is a recognized need for new treatment 
options for type 2 diabetes mellitus (T2DM). 
Recovery of glucose from the glomerular filtrate 
represents an important mechanism in maintaining 
glucose homeostasis and represents a novel target 
for the management of T2DM. Recovery of glucose 
from the glomerular filtrate is executed principally 
by the type 2 sodium-glucose cotransporter 
(SGLT2). Inhibition of SGLT2 promotes glucose 
excretion and normalizes glycemia in animal 
models. First reports of specifically designed SGLT2 
inhibitors began to appear in the second half of 
the 1990s. Several candidate SGLT2 inhibitors are 
currently under development, with four in the 
later stages of clinical testing. The safety profile of 
SGLT2 inhibitors is expected to be good, as their 
target is a highly specific membrane transporter 
expressed almost exclusively within the renal 
tubules. One safety concern is that of glycosuria, 
which could predispose patients to increased 
urinary tract infections. So far the reported safety 
profile of SGLT2 inhibitors in clinical studies 
appears to confirm that the class is well tolerated. 
Where SGLT2 inhibitors will fit in the current 
cascade of treatments for T2DM has yet to be 
established. The expected favorable safety profile 
and insulin-independent mechanism of action 
appear to support their use in combination with 
other antidiabetic drugs. Promotion of glucose 
excretion introduces the opportunity to clear 
calories (80-90 g [300-400 calories] of glucose per 
day) in patients that are generally overweight, and 
is expected to work synergistically with weight 
reduction programs. Experience will most likely 
lead to better understanding of which patients 
are likely to respond best to SGLT2 inhibitors, and 
under what circumstances. 
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INTRODUCTION 
Type 2 diabetes mellitus (T2DM) is a growing 
epidemic: in the United States of America alone, 
nearly 25.8 million people (approx 8.3% of the 
total population) have the disease.1 Estimates 
have placed the global prevalence of the disease 
at around 217 million.2 The consequence 
to the individual of prolonged exposure to 
hyperglycemia is a marked increase in the risk 
of mortality and morbidity, with an associated 
reduction in life expectancy of around 12-13 
years.3 Diagnosis usually occurs some time 
after development of the disease and they have 
often already experienced occult pathology 
by the time patients receive a diagnosis. Early 
adoption of an aggressive approach to disease 
management improves patient outcome, with 
marked reductions in morbidity and mortality.4-6
The first line approach to treatment is 
through lifestyle modification.7 However, T2DM 
is progressive in nature, and lifestyle changes 
sufficient to halt the disease are difficult to 
achieve. Intense efforts by patients and the 
healthcare team frequently fail. Similarly, most 
conventional antidiabetic drugs (eg, metformin, 
sulfonylureas etc.) often fail to slow the 
progression of T2DM, despite the availability 
of a broad range of agents employing different 
mechanisms of action.7-9 The progressive nature 
of the disease and how it overwhelms available 
therapies was highlighted in the UKPDS study; 
suggesting that fewer than half of all patients 
actually achieve adequate levels of disease 
control.4,5
There is a recognized need for new treatment 
options for T2DM. Characterization of the 
mechanisms facilitating glucose resorption 
by the kidney has raised the possibility of 
a novel treatment for diabetes: inhibition 
of the type 2 sodium-glucose transporter 
(SGLT2), a 672 amino-acid, high capacity, low 
affinity transmembrane protein that promotes 
reabsorption of glucose as the glomerular filtrate 
passes down the nephrons.10 Several candidate 
molecules are currently in development and 
may soon be available for use in the treatment 
of diabetes. We provide a brief review of 
SGLT2 inhibitors and their possible role in the 
treatment of T2DM. 
ROLE OF SODIUM GLUCOSE 
TRANSPORTER IN RENAL GLUCOSE 
EXCRETION
Most (>99%) of the plasma glucose entering 
the kidney filters into the nephrons though the 
glomeruli. Under normal circumstances, the 
reabsorptive capacity of the early part of the 
nephron, the proximal tubule, is sufficient to 
clear the filtered glucose load from the luminal 
fluid before it enters the Loop of Henlé. In 
normal individuals, around 180 g of glucose 
passes into the proximal tubules each day, from 
where it is almost completely reabsorbed.11,12 
As plasma glucose concentrations increase, 
the filtered glucose load increases in a linear 
manner. When the rate of glucose entering the 
nephron rises above 260-350 mg/min/1.73 m2, 
for example in patients with diabetes, the excess 
glucose outstrips resorptive capacity and appears 
in the urine (glycosuria).13 In a healthy adult, 
this equates to a blood glucose concentration 
of approximately 11 mmol/L (200 mg/dL).14 
As much as 90% of the filtered glucose load is 
extracted in the S1 segment, and the remaining 
10% is removed in the distal straight tubules
(S2 and S3 segments) (Figure 1). Until recently, 
the mechanisms behind glucose reabsorption 
were poorly understood, although it was 
proposed as early as 1960 that glucose trans-
membrane flux could be achieved through 
the coupling of glucose transport with that of 
sodium.15Diabetes Ther (2011)  2(3):133-145. 135
Since the start of the 20th century, phlorizin, 
a toxic 2’-glucoside of phloretin, has been 
known to increase glycosuria, and has been 
used in the study of renal function.16,17 
During the 1930s, phlorizin was used in
non-invasive human experiments that revealed 
some of the fundamental mechanisms of renal 
hemodynamics and metabolic transport.18 
In the 1950s, studies delineated phlorizin’s 
mechanism of action on inhibition of glucose 
transport in the kidney and small intestine at 
the cellular and molecular levels. Renal micro-
puncture studies conducted with phlorizin 
in the 1970s showed that the transporter was 
located in the brush border of the proximal 
tubule, and that sodium was required 
for the renal absorption of glucose.11,19,20
Studies performed since then confirmed that 
phlorizin is a competitive inhibitor of glucose 
transport, with a binding affinity for the 
transporter that is 1000- to 3000-fold greater 
than that of glucose.21
The rabbit homolog of the human type 1 
sodium-glucose transporter (SGLT1), which 
is coded by the SLC5A gene, was the first 
mammalian cotransporter carrier protein 
to be identified, cloned, and sequenced.22
A family of SLC5A gene sodium-dependent 
transporters has since been sequenced and 
identified in a broad range of tissues.23,24 SGLT1 
and SGLT2 are, perhaps, the SLC5A family 
members that have received greatest coverage 
within the literature. The high affinity, low 
capacity SLGT1 is the main gastrointestinal 
glucose transporter. However, SLGT1 accounts 
for only a small proportion of renal tubular 
glucose reabsortion. The relatively widespread 
distribution of SGLT1 is contrasted by the 
almost exclusive expression on the luminal 
surface of proximal tubules (mainly in the renal 
cortex) of the low glucose affinity, high capacity 
SGLT2, responsible for most renal tubular 
glucose reabsorption.22-26 Cellular glucose and 
sodium uptake occurs in a 1:1 ratio (Figure 2).
The sodium:potassium adenosine triphosphatase 
(ATP) pump transports sodium across the 
basolateral surface into the intracellular fluid, 
maintaining the physiological levels of sodium 
in the cell. The inward sodium concentration 
gradient drives the ‘uphill’ glucose reabsorption 
(a secondary active transport mechanism). 
Cellular glucose concentrations are maintained 
by facilitative glucose outflow through 
transporters in the basolateral membrane of 
the cell. After binding intracellular glucose the 
transporters undergo a conformational change 
that subsequently moderates the movement of 
glucose (down its concentration gradient) back 
into the blood (Figure 3).
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Figure 1. Summary of glucose reabsorption from the lumen 
of the nephrons. Glucose concentration in the glomerular 
filtrate reflects plasma concentration. In most normal 
healthy subjects, the majority of glucose reabsorption is 
believed to occur in the early part of the proximal tubule.136 Diabetes Ther (2011)  2(3):133-145.
SGLT2 INHIBITORS
The antidiabetic properties of phlorizin 
were investigated in the 1980s. In partially 
pancreatectomized rats, phlorizin increased 
glucose secretion in urine and this was associated 
with a normalizing of plasma glucose, without 
inducing hypoglycemia.17 Despite its promising
in vitro properties, phlorizin does not fit the profile 
that we have come to expect from a modern 
therapeutic agent. Phlorizin is hydrolyzed to 
phloretin in the gut, resulting in poor oral 
bioavailability. Phlorizin is also potentially toxic 
and is non-selective, inhibiting both SGLT1 and 
SGLT2 transporters. In the last decade, several 
alternative candidate molecules, targeted to 
specifically inhibit SGLT2, have been investigated 
in both pre-clinical and clinical settings.27 The 
aim has been to take advantage of the potential 
for ‘turning-off’ glucose reabsorption as a new 
therapeutic target for the treatment of T2DM. 
First reports of devised SGLT2 inhibitors 
started to emerge in the scientific literature in 
the second half of the 1990s. Developed with 
a view to overcoming the shortcomings of 
phlorizin, SGLT2 inhibitors represented a new 
mechanism to manage hyperglycemia that 
acted independently of insulin and irrespective 
of patients’ glycemic status. First indications 
suggest that the mechanism of action, which is 
independent of insulin, further reduces glycemia 
when used in combination with traditional 
antidiabetic treatments. 
Results with early compounds were 
promising in terms of specificity for the 
transporter: the compound T-1095 has inhibitory 
capacity for SGLT2 that is 4-fold greater 
than for SGLT1.25 Pharmacodynamic studies 
demonstrated attenuated hyperinsulinemia and 
hypertriglyceridemia in KK rats following oral 
administration of T-1095.26 Lowering of insulin 
resistance and HbA1c levels along with normalized 
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Figure 2. Representation of the 1:1 transport of sodium and 
glucose across the luminal membrane of the epithelial cells of 
the early part of the proximal tubule facilitated by SGLT2.
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Figure 3. Summary of the glucose transport cascade in 
the brush border epithelial cells of the proximal tubule 
demonstrating how the process is driven by the sodium 
gradient maintained by the Na+-K+ ATPase of the basal 
membrane.Diabetes Ther (2011)  2(3):133-145. 137
hepatic glucose production and glucose utilization 
rate were also observed in streptozotocin-
induced diabetic rats26,28 and Zucker diabetic fatty 
rats28,29 following oral administration of T-1095. 
Long-term administration of T-1095 restored 
impaired insulin secretion from pancreatic 
β-cells in Goto-Kakizaki (GK) rats30 and 
suppressed diabetic complications in both 
C57BL/KsJ-db/db mice and GK rats.31,32 However, 
retained co-inhibition of SGLT1 by T-1095 
led to development of the compound being 
discontinued in 2003, having reached phase II 
clinical trials. 
Various SGLT2 inhibitors based on the 
glucoside structure of phlorizin have since 
been proposed (Table 1), and narratives of the 
Table 1. Candidate SGLT2 inhibitors.
Derivative  Example structure  Candidate molecules
Phlorizin  NA  NA
O-glucosides  R =   T-1095 
    AVE-2268 
    Remogliflozin 
    Sergliflozin 
    WAY-123783
  Sergliflozin 
C-glucosides  R =  ASP1941 
    BI-10773 
    BI44847 
    Canagliflozin 
    Dapagliflozin 
  *Parent  LX 4211 
    YM-543
Dioxa-bicyclo [3.2.1] octane  Unknown  PF-04971729 
(bridged ketal) ring system 
Antisense oligonucleotides  Unknown  ISIS-388626
Manufacturers: Johnson & Johnson/Tanabe Seiyaku Co. Ltd (Japan) (T-1095); Sanofi-Aventis (AVE-2268); 
 GlaxoSmithKline (remogliflozin/KGT 1681/sergliflozin); Wyeth (WAY-123783); Astellas Pharma Inc (ASP 1941/YM-
543); Boehringer Ingelheim GmbH (BI-10773/BI-44847); Boehringer Ingelheim, GmbH/Ajinomoto (canagliflozin); 
Johnson & Johnson/Tanabe Mitsubishi (TA-7284/JNJ 28431754); Bristol-Myers Squibb Co/AstraZeneca (dapagliflozin); 
Lexicon (LX 4211); Isis Pharmaceuticals (ISIS 388626); Roche/Chugai (R7201/CSG452); Pfizer (PF-04971729).
Candidate molecules have also been registered by Kissei, Taisho, Theracos, and Daiichi Sankyo.
NA; not applicable.138 Diabetes Ther (2011)  2(3):133-145.
discovery pathway of the different inhibitors have 
recently been published.27,33 The glucoside moiety 
of phlorizin binds to SGLT2 transporters and the 
‘O’-linked phenolic distal ring is responsible for its 
inhibitory properties.34 Structure-activity analysis 
of the parent molecule shows that addition of 
lipophilic groups to the distal ring augments the 
inhibition of the SGLT2 transporter, and increases 
selectivity for SGLT2 over SGLT1.25 However, the 
O-linkage is a metabolic target for β-glucosidase 
enzymes that can curtail the activity of SGLT2 
inhibitors  in vivo. To address this possible 
limitation to therapeutic utility, candidate 
SGLT2 inhibitors have been synthesized that 
employ a C-glucoside linkage (Table 1). Both the
O- and C-glucosides appear to bind to a single 
site on the SGLT2 transporter. The aromatic and 
heteroaromatic C-glucosides are metabolically 
more stable than O-glucosides, due to their relative 
resistance to hydrolysis. Alternative candidate 
SGLT2 inhibitors that have also been considered 
include modified sugar rings, N-glucosides and, 
more recently, a bridged ketal ring.35
Another approach uses antisense 
oligonucleotides to inhibit expression of 
SGLT2. Administration of synthesized strands 
of nucleic acid targeted to specifically bind to 
SGLT2 messenger RNA blocks the transporter’s 
translation, protein production, and expression 
in the cells of the proximal tubule.
A summary of the status of inhibitor 
development is provided in Table 2.36-54
Table 2. Clinical status of SGLT2 molecules. 
     Clintrial.gov   
     studies  Literature 
Compound  Phase  Company  completed/total  citations
C-glucosides
Dapagliflozin   III  Bristol-Myers Squibb Co./AstraZeneca  38/47  [36] [37] [38] [39] 
(BMS-512148)       [40] [41] [42]
Canagliflozin   III  Johnson & Johnson/Tanabe Mitsubishi  7/26  [43] [44] [45] [46] 
(TA-7284, JNJ 28431754)       [47]
ASP-1941  III  Astellas Pharma Inc./Kotobuki  18/27  [48] [49]
BI-10773  III  Boehringer Ingelheim  16/31  -
LX-4211  II  Lexicon Pharmaceuticals  4/4  -
DSP-3235   I  GlaxoSmithKline/Dainippon Sumitomo   1/1  - 
(KGA-3235, GSK 1614235,   (under license from Kissei 
1614235)    Pharmaceuticals) 
O-glucosides
Sergliflozin (GW869682)  II  GlaxoSmithKline  3/3  [50] [51] [34]
Remogliflozin (KGT 1681)  II  GlaxoSmithKline/Kissei  16/16  [52] [53] [54]
AVE-2268  -  Sanofi-Aventis  1/1  -
YM-543  IIa  Astellas Pharmaceutical Inc/Kotobuki  1/1  -
Other
ISIS-SGLT2Rx (ISIS-388626)  I  Isis Pharmaceuticals  1/1  -
PF04971729  II  Pfizer  7/8  -Diabetes Ther (2011)  2(3):133-145. 139
CLINICAL EXPECTATIONS FOR 
SGLT-2 INHIBITORS
As the above discussion suggests, there are 
several hypothetical reasons why the SGLT2 
transporter represents an opportune target 
for managing blood glucose. However, the 
challenge is to establish therapeutic utility while 
demonstrating an acceptable safety profile. 
A detailed summary of clinical findings has 
recently been published.55
Efficacy 
The mechanism of action of SGLT2 inhibitors 
predicts a beneficial effect, but the long-term 
glucose lowering capacity in a clinical setting 
may not impart significant reductions in 
HbA1c. Modest HbA1c lowering in the region of
0.5%-0.9%, that may be predicted from early 
clinical studies, would be comparable to 
that achieved with other currently marketed 
oral agents.55 It remains to be seen whether 
promoting glucose excretion will result in 
long-term benefits for the patient in terms of 
returning metabolic balance, or even weight loss. 
Clearly, blocking glucose reabsorption permits 
the clearance of glucose from the body, and thus 
must eventually serve to reduce levels of plasma 
glucose. The amount of glucose available for 
excretion is dependent on the amount entering 
the nephrons, which, in turn, depends on blood 
glucose concentration at the glomerulus. Thus, 
the amount of glucose excreted is greater when 
the blood plasma glucose concentrations are 
highest. In effect, glucose ‘removal’ might be 
expected only to be greatest at times when it is 
most needed (when glucose levels are highest), 
such as during post-prandial hyperglycemia. 
The benefit to those patients in whom 
treatment has provided mild-to-moderate 
glycemic control might be questioned,
as the potential for glucose excretion would be 
relatively low. Nevertheless, patients who achieve 
moderate glycemic control may be exposed 
to clinically relevant post-prandial glucose 
excursions that can impart disproportionate 
effects on HbA1c and possibly the morbidity 
and mortality associated with T2DM.56 In such 
a patient population, SGLT2 inhibitors might 
attenuate the impact of post-prandial glucose 
spikes. Nevertheless, clinical experience with 
agents, such as the meglitinides, that target 
post-prandial glucose control, suggest that the 
clinical benefit of this approach is disappointing. 
Treatments targeting post-prandial glucose levels 
provide little more than modest improvements 
in HbA1c with little evidence of long-term 
outcome benefits for patients.57
As SGLT2 may be responsible for as much as 
90% of glucose reabsorption by the kidney, there 
is the clinical potential for as much as 160 g 
of glucose to be excreted each day following 
effective SGLT2 inhibition.23 However, it appears 
that the actual glucose loss achieved in clinical 
studies is only about half that predicted.38 It 
is not clear whether this is a consequence of 
compensating mechanisms undertaking tubular 
reabsorption or incomplete inhibition of the 
transporter.
Safety
Thus far, the safety profile of SGLT2 inhibitors 
reported from clinical studies appears to fulfill 
expectations.33,34,55,40,58 SGLT2 inhibitors are 
‘designed’ to target a highly specific membrane 
transporter that is almost exclusively expressed 
within the renal tubules. Clearly, compared with 
less specific molecules, the potential for cross-
reaction should be low. It is also unlikely that 
SGLT2 inhibitors will induce hypoglycemia, 
since when plasma glucose levels are low the 
amount of glucose excreted will also be low.59140 Diabetes Ther (2011)  2(3):133-145.
This prediction appears to be confirmed by 
clinical studies reported thus far, which show 
no apparent increases in hypoglycemic episodes 
with SGLT2 inhibitors.50,60 Even when SGLT2 is 
blocked completely, a degree of renal glucose 
recovery is maintained via the relatively 
unhindered SGLT1 transporter. 
One aspect of SGLT2 inhibition that has been 
raised as a potential issue of safety concern is that 
of glycosuria, which could predispose patients 
to increased urinary tract infections (UTI). 
The extent to which increases in infection will 
occur has yet to be established. There have been 
some reports of infection in clinical studies.60,61 
However, a study that reviewed risk factors 
for developing UTIs in women with diabetes 
observed that glucosuria was not a significant 
contributing factor.62
Interestingly, there is a rare group of 
individuals who do not express the SGLT2 
transporter or in which its functionality has 
been partially or completely lost due to a 
genetic mutation for which both an autosomal 
recessive and dominant pattern of inheritance 
has been reported. These people do not appear 
to suffer any ill consequences, suggesting that 
blockade of the transporter per se in T2DM 
patients would offer no immediate risk. Patients 
expressing these mutations have decreased 
renal tubular reabsortion of glucose from the 
lumen in the absence of hyperglycemia, or any 
other signs of tubular dysfunction. It is not 
clear whether familial renal glucosuria (due 
to SGLT2 mutation) protects against T2DM; 
although SGLT2 deletion in animal models 
appears to improve glucose homeostasis and 
preserve pancreatic β-cell function.63 We did 
not find any recorded evidence of an increased 
disposition to urinary tract or vulvovaginal 
infections, although identification and study of 
these subjects is difficult due to the rarity of the 
disease. Clearly, clinical development programs 
will need to address the concern of a possible 
increased risk of UTI. 
Increased glucose content in the urine 
following SGLT2 inhibition will likely serve to 
increase urinary flow as a consequence of the 
osmotic diuretic effect in the lumen of the 
nephron. This could result in modest, possibly 
beneficial, reductions in blood pressure, but 
raises additional safety concerns associated with 
possible loss of fluid and solutes. This may be of 
particular concern in elderly patients or those 
who do not have the capacity to maintain their 
fluid balance. However, it should be noted that 
the effect is considerably lower than that seen 
with frequently used loop diuretics and there 
is no apparent change in glomerular filtration 
rate that would be indicative of a direct effect 
on renal function. Simple instructions on 
maintaining a state of hydration with regular 
drinks may serve to overcome the concerns over 
both urinary infection and fluid imbalance. 
POSITIONING THE SGLT2 
INHIBITORS
The question arises as to where SGLT2 inhibitors 
might fit in the current cascade of treatments 
for the management of T2DM. While treatment 
of T2DM follows prescribed guidelines, there 
are many approaches and permutations to their 
application in clinical practice. Initial treatment 
strategies involve lifestyle interventions to 
promote weight loss and improve glycemic 
control. Although the SGLT2 inhibitors’ 
mechanism of action would make them suitable 
for initial monotherapy in patients with early 
stage T2DM, it is unlikely they would be 
considered at this stage. Most treatments are 
currently initiated with metformin, which is 
relatively inexpensive, has a good historical 
safety profile, and is efficacious. Clearly, when 
they are first launched, the SGLT2 inhibitors Diabetes Ther (2011)  2(3):133-145. 141
will not be able to compete with metformin, 
purely on the issue of cost. If considered as 
second line treatment, SGLT2 inhibitors may 
offer a synergistic effect. However, as explained 
earlier, the advantage of this may be minimal in 
patients achieving a degree of glycemic control. 
By promoting an ‘escape’ mechanism for 
glucose, SGLT2 inhibitors introduce a new mode 
to the control of T2DM. With the exception of 
α-glucosidase inhibitors, which block glucose 
uptake from the gut, all currently available 
antidiabetic therapies directly or indirectly 
modulate insulin to manipulate endogenous 
glucose utilization. Despite the modest effect 
on HbA1c predicted for SGLT2 inhibitors, the 
introduction of a novel means of reducing 
hyperglycemia increases the treatment options 
available to physicians for a disease that 
frequently requires the use of multiple agents 
to achieve control targets.57 The expected 
favorable safety profile and insulin-independent 
mechanism of action appear to support the use 
of SGLT2 inhibitors in combination with other 
antidiabetic drugs. Insulin-dependent therapies 
become less effective with the development 
of insulin resistance and/or deterioration of 
β-cell function; particularly in patients with 
low insulin resistance (high glucose) or poorly 
controlled disease. The insulin-independent 
action of SGLT2 inhibitors suggests potential 
for a synergistic effect in such scenarios. The 
insulin-independent action of SGLT2 inhibitors 
also means that they may be of use in type 1 
diabetes, perhaps as a means of moderating
post-prandial glucose excursions. 
By increasing excretion of glucose, SGLT2 
inhibitors offer an opportunity to increase 
calorie loss in T2DM patients, most of 
whom are overweight. The continual loss of
80-90 g of glucose per day (300-400 calories) 
is a significant loss of calories that should 
work synergistically with weight reduction 
programs.64 Short-term studies in both animals 
and man appear to confirm the predicted weight 
reducing property. This contrasts with several 
drug therapies, including sulfonylureas, insulin, 
and thiazolidinediones, which are generally 
associated with weight gain.65,66 But there are 
currently no data to confirm whether the rate 
of calorie loss continues with chronic therapy.
In a clinical setting it would be easy to 
overcome any ‘benefits’ that patients may derive 
from SGLT2 inhibition if they perceived the 
drug as a means of ‘escaping’ strict adherence 
to lifestyle modifications. In addition, it 
has yet to be established whether patients 
‘acclimatized’ to higher levels of plasma glucose 
would experience a marked change in appetite 
with substantial loss of glucose/calories.67
One final issue is that for these drugs to work, 
they need to be delivered to the epithelial 
luminal surface of the nephron, requiring them 
to be cleared by the glomerulus. Consequently, 
their efficacy may be affected in those instances 
when the functioning of the kidney is impaired, 
for example in diabetic nephropathy. However, 
this has yet to be confirmed clinically or in any 
animal model.
CONCLUSION
Most patients with T2DM eventually succumb to 
the progressive nature of the disease and will, at 
some point, require multiple therapies to attain 
treatment targets. Only half the patients with 
T2DM achieve the HbA1c target of less than 7%, 
despite the many different treatment options 
currently available. With SGLT2 inhibitors 
introducing an alternative means of managing 
glucose, we gain a further treatment option 
that may increase our ability to control T2DM. 
Experience will lead to better understanding of 
which patients are likely to respond best, and 
under what circumstances. 142 Diabetes Ther (2011)  2(3):133-145.
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